Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : games trader group -- Ignore unavailable to you. Want to Upgrade?

To: John Paquet who wrote (95)	9/28/1999 11:02:00 AM
From: John Paquet	Read Replies (1) \| Respond to of 507

Here you go Folks, here I say goodbye to our GTR for that $4.00, as I said that GTR will not trade above that $4.00 any more until Y2K. Bye!! $4.00 GTR. John Paquet

To: John Paquet who wrote (95)	9/28/1999 11:46:00 AM
From: mr. ed	Read Replies (1) \| Respond to of 507

Hi Here is a news release but there should be more to follow. The shareholder's meeting is thursday that is my guess for more news. This stock is for real..... Tuesday September 28, 6:59 am Eastern Time Company Press Release SOURCE: Biotech Holdings Ltd. Biotech Signs Chile Licensing Agreement for Its Diabetes Drug, DIAB II VANCOUVER, British Columbia, Sept. 28 /PRNewswire/ -- Robert B. Rieveley, President of Biotech Holdings Ltd. (``Biotech') (OTC Bulletin Board: BIOHF - news), is pleased to announce that Biotech has signed a licensing agreement for the distribution of Biotech's Adult-Onset Diabetes drug, DIAB II, in Chile. Under the agreement, Biotech has granted marketing and distribution rights for seven years to Laboratorios SAVAL. ``SAVAL,' Mr. Rieveley said, ``is one of the most dynamic pharmaceutical companies in Chile. SAVAL, with four hundred employees, is third in sales in the Chilean pharmaceutical market and second in the number of prescriptions filled. SAVAL will co-operate with Biotech in the preparation of a registration dossier for DIAB II in Chile. We believe that SAVAL will prove to be a strong partner for bringing DIAB II to the Chilean market.' In addition to the agreement for Chile, Biotech has licensing agreements for DIAB II in Brazil, Argentina, Venezuela and Peru and is negotiating with pharmaceutical firms in a number of other Latin American markets. For North America and Western Europe, Biotech's business plan is based on the Company's continuing discussions with a number of international pharmaceutical companies to create a relationship that would lead to submitting DIAB II for approval to the US FDA. DIAB II, an oral diabetes drug, is an insulin-receptor sensitizer. DIAB II belongs to a new class of drugs that is used to control the chronically high blood sugar level that typifies diabetes. DIAB II works by improving the patient's ability to utilize both endogenous and injected insulin, the hormone that controls blood sugar levels. Studies of the drug, including a clinical trial recently concluded in Brazil, have shown it to be both effective and safe. Type II Diabetes affects more than 17 million people in North America, over 20 million in Latin America and over 150 million worldwide. Biotech Holdings Ltd. is based in Vancouver, British Columbia and has its laboratory and plant facility in Richmond, BC. Biotech Holdings trades on the Over the Counter Bulletin Board in the United States (OTC BB symbol: BIOHF) and on the Alberta Stock Exchange (ASE symbol: BIO). For inquiries, contact Austin Rand at Biotech Holdings Ltd. 1-888-216-1111 (toll-free), 8 a.m. to 5 p.m. Pacific time, or by e-mail at biotech@direct.ca. Please visit Biotech's website at biotechltd.com. This release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, actual results may differ for reasons that include but are not limited to political and economic conditions in the countries in which the Company does or intends to do business, regulatory action, product pricing and competitive market conditions. These forward-looking statements represent the Company's judgement at the date of this release and any changes in assumptions or external factors could produce significantly different results. SOURCE: Biotech Holdings Ltd.